You just read:

Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders

News provided by

Nektar Therapeutics

27 Mar, 2017, 09:00 ET